Abdominal Or Thoracic Aortic Aneurysm Surgery — Cost, Top Hospitals & Success Rates | MyMedicPlus

An aortic aneurysm is a pathological, localised dilation of the aorta exceeding 1.5 times its normal diameter — defined clinically as 3 cm or more for the infrarenal abdominal aorta and 4 cm or more for the thoracic aorta. The fundamental and lethal danger of an untreated aneurysm is spontaneous rupture, which carries 80-90% overall mortality. Elective surgical repair is therefore recommended before rupture when the aneurysm reaches a critical size threshold: 5.5 cm for abdominal aortic aneurysm (AAA) in men, 5.0 cm in women, or 5.5-6.0 cm for thoracic aneurysms, and for any aneurysm showing rapid expansion of more than 1 cm per year regardless of absolute size.

Two principal surgical strategies govern modern aortic aneurysm management. Open surgical repair involves exposing the aorta through a laparotomy or thoracotomy, clamping the vessel above and below the aneurysm, and replacing the diseased segment with a Dacron or polyester synthetic graft sutured in an end-to-end configuration. It provides highly durable, long-term correction that has been validated over 20-plus years of follow-up. Endovascular aortic repair — designated EVAR for abdominal and TEVAR for thoracic aneurysms — delivers a modular stent-graft system through catheter access via the femoral arteries, deploying it endoluminally to exclude the aneurysm from aortic blood pressure without open surgical clamping or major incision.

Patient selection between open and endovascular approaches depends on aneurysm morphology defined by CT angiography, patient physiological fitness assessed by cardiopulmonary exercise testing (CPET) and echocardiography, and institutional procedural volume. EVAR 30-day mortality at high-volume centres performing more than 50 procedures annually ranges from 0.5-1.5%, compared to 4-5% for elective open repair — a difference that narrows and disappears at 8 years of follow-up. Thoracic EVAR has similarly transformed the management of descending thoracic aneurysms, converting a historically high-risk open thoracotomy procedure into a routine catheter intervention.

For international patients, leading vascular centres in India, Singapore, Germany, and Turkey perform both EVAR and open aortic repair at 40-70% cost savings versus the US or UK private sector, with fully equivalent procedural outcomes when JCI-accredited institutions are selected.

Abdominal aortic aneurysm (AAA) is the primary indication for this surgery, predominantly affecting men over 65 with smoking history, hypertension, hypercholesterolaemia, or peripheral arterial disease. Standard AAA repair addresses the infrarenal segment; juxtarenal and suprarenal AAA — where the aneurysm extends to or above the renal arteries — requires complex fenestrated EVAR or open repair with renal artery reimplantation. Iliac artery aneurysms frequently coexist with AAA and are addressed simultaneously during the bifurcated graft repair.

Thoracic aortic aneurysm (TAA) affects the ascending, arch, or descending thoracic aorta. Ascending TAA is commonly associated with bicuspid aortic valve, Marfan syndrome, or aortic root dilatation; these require open repair via median sternotomy using cardiopulmonary bypass due to proximity to the coronary ostia and aortic valve. Descending thoracic TAA is the primary indication for TEVAR. Thoracoabdominal aortic aneurysm (TAAA), classified by Crawford types I-IV according to extent of visceral involvement, represents the most complex aortic pathology and demands multidisciplinary planning for visceral artery revascularisation and spinal cord protection. Mycotic (infected) aortic aneurysms, though rare, require urgent surgical intervention combined with prolonged intravenous antibiotic therapy and, where anatomy permits, endovascular exclusion.

Candidates for elective AAA repair are men with AAA of 5.5 cm or more, women with AAA of 5.0 cm or more, or any patient with rapid aneurysm expansion of more than 1 cm per year. Symptomatic AAA — presenting with back or flank pain attributable to the aneurysm — warrants urgent repair regardless of size. EVAR is anatomically feasible in approximately 60-70% of AAA cases, requiring a proximal infrarenal neck of at least 15 mm, neck angulation below 60 degrees, and adequate iliac access vessel calibre (minimum 7-8 mm). Open repair is preferred for complex anatomy, younger patients seeking lifetime durability, or when endovascular seal zones cannot achieve reliable exclusion of the aneurysm sac.

Contraindications to elective repair include severe cardiac dysfunction with ejection fraction below 25%, end-stage renal failure, terminal malignancy with life expectancy under 2 years, or severe obstructive lung disease with FEV1 below 1.0 litre. Emergency repair of ruptured AAA overrides most contraindications given the immediate life-threatening nature of the emergency. Patients with connective tissue disorders — Marfan syndrome, Loeys-Dietz syndrome, or vascular Ehlers-Danlos syndrome — require genetic counselling and tailored device selection because connective tissue fragility affects anastomotic strength and demands extended lifelong surveillance of all aortic segments.

Open surgical repair uses a midline laparotomy or left retroperitoneal approach. After aortic clamping, the aneurysm sac is opened longitudinally, back-bleeding lumbar arteries oversewn, and a straight tube graft or bifurcated aortobiiliac graft sutured end-to-end. The aneurysm sac is then wrapped around the graft to protect it from duodenal erosion. For juxtarenal cases, suprarenal clamping and cold renal perfusion are employed, increasing operative complexity but allowing anatomically precise graft placement.

Endovascular aortic repair (EVAR) is performed under biplane fluoroscopic guidance in a hybrid operating room. Modular stent-graft systems — including the Medtronic Endurant II, Cook Zenith Flex, and Gore Excluder — are deployed via bilateral femoral arteriotomies, with the main body and contralateral iliac limb engaged under fluoroscopic control. Completion angiography confirms exclusion of the aneurysm with no endoleak. EVAR can be performed under regional (spinal/epidural) anaesthesia in patients with severe respiratory disease who cannot tolerate general anaesthesia. Fenestrated EVAR (FEVAR) uses custom-manufactured devices with precisely positioned fenestrations or side branches corresponding to the renal and mesenteric arteries, extending endovascular eligibility to juxtarenal and short-neck cases. Thoracic EVAR (TEVAR) deploys purpose-designed thoracic devices with higher radial force to treat descending thoracic aneurysms. Complex arch pathology may require hybrid debranching operations — where arch branch vessels are surgically reimplanted into the ascending aorta before TEVAR deployment — to create a suitable proximal landing zone.

Elective EVAR achieves 30-day mortality of 0.5-1.5% at high-volume centres, compared to 4-5% for open repair, demonstrating a significant short-term survival advantage. The landmark EVAR-1 and DREAM trials confirm this perioperative benefit but demonstrate convergence of all-cause mortality between EVAR and open repair at 8-10 years of follow-up, driven by aneurysm-related re-interventions in the EVAR group that are not required after successful open repair. EVAR requires two to three times more secondary procedures — mainly for endoleak, limb occlusion, or device migration.

Open repair, despite higher short-term risk, provides durability confirmed over more than 20 years without the need for annual imaging-based surveillance. Primary synthetic graft patency exceeds 95% at 10 years. For ruptured AAA managed at centres with 24-hour endovascular capability, emergency EVAR achieves 30-day mortality of 25-35% compared to 40-50% for emergency open repair — though randomised evidence from the IMPROVE trial did not demonstrate superiority of EVAR over open repair in all-comers with ruptured AAA, possibly due to anatomical unsuitability in emergency settings.

Open AAA repair carries risks of myocardial infarction in 5% of patients, acute kidney injury requiring temporary dialysis in 3-5%, lower limb ischaemia in 1-2%, spinal cord ischaemia causing paraplegia in less than 1% for infrarenal cases (rising to 3-7% for thoracoabdominal repair), and ischaemic colitis from inferior mesenteric artery ligation in approximately 1%. Retrograde ejaculation from disruption of the presacral autonomic nerve plexus affects 20-30% of men. Late graft infection, though rare at 0.5-1%, is a devastating complication that may present years after implantation with fever, back pain, and aortoenteric fistula, requiring complete graft explantation and extra-anatomic reconstruction.

EVAR-specific complications include endoleak — classified as type I (proximal or distal seal zone failure, 5-15%), type II (collateral vessel back-pressurisation, 20-25%), type III (fabric tear or modular junction leak, 2%), and type IV (graft fabric porosity, less than 1%). Type I and III endoleaks require urgent re-intervention; type II endoleaks are monitored serially and selectively embolised when sac enlargement occurs. Stent-graft limb occlusion affects 2-5% of EVAR patients. Post-implantation syndrome — fever, elevated inflammatory markers without infection — is self-limiting and affects 30-60% of EVAR patients in the first two weeks.

Following open repair, ICU admission for 24-48 hours is standard, followed by high-dependency care for 3-5 days and total hospitalisation of 7-14 days. Enhanced recovery pathways incorporating epidural analgesia, early enteral nutrition, and physiotherapy-directed mobilisation have reduced hospital stay by 2-3 days compared to traditional care. Patients recover full ambulatory capacity by 4-6 weeks and may return to sedentary work at 6-8 weeks. Heavy lifting restriction for 3 months allows abdominal wall healing. Lifelong annual ultrasound of any residual aortic segments is recommended.

After EVAR, patients are discharged within 2-4 days. The mandatory CT angiography surveillance protocol consists of imaging at 1 month, 12 months, and annually thereafter to detect endoleak, sac diameter change, device migration, or limb occlusion — this lifelong commitment is the key trade-off of the endovascular approach. Normal daily activities may resume within 2 weeks; vigorous exercise is restricted for 4 weeks. Lifelong antiplatelet therapy (aspirin 75-100 mg daily), high-intensity statin therapy, and blood pressure maintenance below 130/80 mmHg are prescribed universally. Absolute smoking cessation is the single most important modifiable intervention to prevent disease progression and contralateral aortic expansion.

EVAR in the United States costs $40,000-$80,000 including hospitalisation, the stent-graft device (which alone costs $12,000-$20,000), operating theatre fees, surgeon, and anaesthesia. Open AAA repair costs $30,000-$60,000 for uncomplicated cases, rising significantly with ICU complications. Thoracoabdominal repair at a US centre of excellence exceeds $100,000. In the United Kingdom under private care, EVAR costs £20,000-£40,000 and open repair £18,000-£35,000.

At JCI-accredited hospitals in India — Apollo Hospitals Delhi, Fortis Escorts Heart Institute Mumbai, Asian Heart Institute Mumbai — EVAR costs $12,000-$20,000 and open repair $10,000-$18,000, representing 60-75% savings versus US prices. Singapore (National Heart Centre, Mount Elizabeth Hospital) charges $25,000-$40,000 for EVAR. Germany offers EVAR at €15,000-€30,000 with internationally recognised surgical expertise. Thailand (Bumrungrad International Hospital, Bangkok Heart Hospital) performs EVAR at $15,000-$25,000. Patients save 40-70% through medical tourism at accredited vascular surgery centres.

Conservative surveillance with serial imaging — ultrasound every 6 months for aneurysms of 4.5-5.4 cm and annually for those below 4.5 cm — is the standard management for small aneurysms below repair threshold. Optimised medical therapy including rigorous blood pressure control below 130/80 mmHg, high-intensity statin therapy, antiplatelet therapy, and complete smoking cessation reduces cardiovascular risk and may modestly slow aneurysm expansion rate, but has not been proven to delay the need for repair in adequately powered randomised trials.

Fenestrated and branched endovascular devices have progressively expanded anatomical eligibility for minimally invasive repair to include complex juxtarenal and thoracoabdominal configurations previously limited to open surgery. For patients physiologically unsuitable for both open and endovascular repair, palliative management and optimised medical therapy are appropriate. Research into pharmacological inhibition of matrix metalloproteinases — enzymes responsible for extracellular matrix degradation in aneurysm walls — is ongoing with doxycycline and other agents but has not yet yielded clinically proven disease-modifying treatments.